YARS2 encodes the mitochondrial tyrosyl-tRNA synthetase that catalyzes the covalent binding of tyrosine to its cognate mt-tRNA. Mutations in YARS2 have been identified in patients with myopathy, lactic acidosis, and sideroblastic anemia type 2 (MLASA2). We report here on two siblings with a novel mutation and a review of literature. The older patient presented at 2 months with marked anemia and lactic acidemia. He required periodic blood transfusions until 14 months of age. Cognitive and motor development was normal. His younger sister was diagnosed at birth, presenting with anemia and lactic acidosis at 1 month of age requiring periodical transfusions. She is now 14 months old and doing well. For both our patients, there was no clinical evidence of muscle involvement. We found a new homozygous mutation in YARS2, located in the α-anticodon-binding (αACB) domain, involved in the interaction with the anticodon of the cognate mt-tRNATyr.
Our study confirms that MLASA must be considered in patients with congenital sideroblastic anemia and underlines the importance of early diagnosis and supportive therapy in order to prevent severe complications. Clinical severity is variable among YARS2-reported patients: our review of the literature suggests a possible phenotype-genotype correlation, although this should be confirmed in a larger population.
Mitochondria Myopathy, lactic acidosis, and sideroblastic anemia Tyrosyl-tRNA synthetase YARS2
This is a preview of subscription content, log in to check access.
This work was supported by Fondazione Pierfranco e Luisa Mariani (CM23), Fondazione Telethon (grant GGP11011), Cell line and DNA Bank of Genetic Movement Disorders and Mitochondrial Disesases of Telethon Network of Genetics Biobanks (grant GTB12001) and the Italian Association of Mitochondrial Disease Patients and Families (Mitocon ONLUS).
Bonnefond L, Frugier M, Touzé E et al (2007) Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features. Structure 15:1505–1516CrossRefPubMedGoogle Scholar
Burrage LC, Tang S, Wang J et al (2014) Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G>A) in the mitochondrial encoded ATP6 gene. Mol Genet Metab 14:S1096–S7192Google Scholar
Bykhovskaya Y, Casas K, Mengesha E, Inbal A, Fischel-Ghodsian N (2004) Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet 74:1303–1308CrossRefPubMedCentralPubMedGoogle Scholar
Edwards H, Schimmel P (1987) An E. coli aminoacyl-tRNA synthetase can substitute for yeast mitochondrial enzyme function in vivo. Cell 51:6439–6649CrossRefGoogle Scholar
Fernandez-Vizarra E, Berardinelli A, Valente L, Tiranti V, Zeviani M (2007) Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA). J Med Genet 44:173–180CrossRefPubMedCentralPubMedGoogle Scholar
Fujiwara T, Harigae H (2013) Pathophysiology and genetic mutations in congenital sideroblastic anemia. Pediatr Int 55:675–679CrossRefPubMedGoogle Scholar
Hallmann K, Zsurka G, Moskau-Hartmann S et al (2014) A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy. Neurology 83:2183–2187CrossRefPubMedGoogle Scholar
Konovalova S, Tyynismaa H (2013) Mitochondrial aminoacyl-tRNA synthetases in human disease. Mol Genet Metab 108:206–211CrossRefPubMedGoogle Scholar
Nakajima J, Eminoglu TF, Vatansever G et al (2014) A novel homozygous YARS2 mutation causes severe myopathy, lactic acidosis, and sideroblastic anemia 2. J Hum Genet 59:229–232CrossRefPubMedGoogle Scholar
Riley LG, Cooper S, Hickey P et al (2010) Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia-MLASA syndrome. Am J Hum Genet 87:52–59CrossRefPubMedCentralPubMedGoogle Scholar
Riley LG, Menezes MJ, Rudinger-Thirion J et al (2013) Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia. Orphanet J Rare Dis 8:193CrossRefPubMedCentralPubMedGoogle Scholar
Rötig A (2011) Human diseases with impaired mitochondrial protein synthesis. Biochim Biophys Acta 1807:1198–1205CrossRefPubMedGoogle Scholar
Sasarman F, Nishimura T, Thiffault I, Shoubridge EA (2012) A novel mutation in YARS2 causes myopathy with lactic acidosis and sideroblastic anemia. Hum Mutat 33:1201–1206CrossRefPubMedGoogle Scholar
Schwartzentruber J, Buhas D, Majewski J et al (2014) Mutation in The Nuclear-Encoded Mitochondrial Isoleucyl-tRNA Synthetase IARS2 in Patients with Cataracts, Growth Hormone Deficiency with Short Stature, Partial Sensorineural Deafness, and Peripheral Neuropathy or with Leigh Syndrome. Hum Mutat 35:1285–1289PubMedGoogle Scholar
Shahni R, Wedatilake Y, Cleary MA, Lindley KJ, Sibson KR, Rahman S (2013) A distinct mitochondrial myopathy, lactic acidosis and sideroblastic anemia (MLASA) phenotype associates with YARS2 mutations. Am J Med Genet 161:2334–2338CrossRefPubMedCentralGoogle Scholar